Skip to main content
Premium Trial:

Request an Annual Quote

Isis to Receive $1.1M from Alnylam

Premium

Isis Pharmaceuticals this week said that it stands to receive a $1.1 million payment tied to Alnylam Pharmaceuticals' strategic alliance with Genyzme.

This week, Alnylam announced that it has partnered with Genzyme to develop and commercialize RNAi-based treatments for TTR-mediated amyloidosis. Genzyme will have product rights in Asia (see related story, this issue).

Isis said that the money, to be paid by Alnylam, reflects its share of the upfront fees Alnylam is receiving from Genzyme. Isis is entitled to a portion of payments Alnylam receives on licenses to products enabled by Isis intellectual property pursuant to their ongoing IP cross-licensing arrangement.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.